ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Credit: Getty Images This patient fact sheet on sleep apnea and obesity discusses the bidirectional relationship between these 2 conditions and potential treatments. Our easy-to-read fact sheets ...

The FDA has expanded the approval of Eli Lillys obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication approved for ...

Tirzepatide (Zepbound and Mounjaro), which is approved for chronic weight management and treatment of type 2 diabetes, has significant benefits for patients with moderate-to-severe obstructive sleep ...

Please provide your email address to receive an email when new articles are posted on . In patients with obesity and obstructive sleep apnea, weight-loss surgery was linked to reduced risk for heart ...

Medically reviewed by Daniel Combs, MD Key Takeaways Obstructive sleep apnea (OSA) occurs when the upper airway gets blocked ...